Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma

Detalhes bibliográficos
Autor(a) principal: Inácio,Cristiano Machado
Data de Publicação: 2010
Outros Autores: Dietz,Ulrich Andréas, Malafaia,Osvaldo, Ribas Filho,Jurandir Marcondes, Nassif,Paulo Afonso Nunes, Czeczko,Nicolau Gregori, Marcondes,Carmen Australia Paredes
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Acta Cirúrgica Brasileira (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502010000100020
Resumo: PURPOSE: To evaluate the development of Walker 256 tumor in male Wistar rats treated with tacrolimus using an experimental kidney tumor model. METHODS: 40 male Wistar rats were divided into four groups: Tumor group (TU) (n=10), Tacrolimus-Tumor group (TT) (n=10), Tacrolimus group (TC) (n=10) and Control group (C) (n=10). Treatment with tacrolimus was performed in groups TT and TC. Under anesthesia, the right kidney of each animal of TU and TT was accessed through a supraumbilical incision and inoculated with a 0.1mL solution containing 2x10(6) tumor cells (Walker 256 carcinosarcoma tumor cells). Group TC was treated with a saline solution. All the animals of groups TC and TT were treated with tacrolimus (5mg/kg/day) by gavage for 15 days. TU group animals received saline by gavage for 15 days. On the 15th postoperative day, all animals were submitted to euthanasia and blood sampling for analysis of serum creatinine (Cr) and blood urea nitrogen (BUN). Abdominal gross examination was performed, the right kidney removed and prepared for histological analysis by hematoxylin-eosin staining. The resulting data were submitted to statistical analysis by ANOVA. RESULTS: Statistical significance was found when comparing creatinine level between groups TU, TT and TC -TT group culminated with a marked increased in creatinine levels (Cr=1.013 ± 0.3028 mg/mL), TU group (Cr=0.5670 ± 0.03536 mg/dL) P=0.00256, TC group (Cr =0.711 ± 0.1653 mg/mL) P= 0.02832. Statistical significance was found when comparing BUN levels in TT group (71.32 ± 17.14 mg/mL), compared with TU group (45.83 ± 5.046 mg/dL), P=0.000318. There were no statistically significant differences between groups TT and TC (61.23 ± 9.503 mg/mL) P=0.7242. Histological analysis showed a poor evolution in TT group with multiple foci of hemorrhage and cortical invasion by the Walker tumor. CONCLUSION: The Tacrolimus-treated group developed a more aggressive tumor and a drug-related nephrotoxic effect.
id SBDPC-1_3b6af155132932be77fa50fc790998c2
oai_identifier_str oai:scielo:S0102-86502010000100020
network_acronym_str SBDPC-1
network_name_str Acta Cirúrgica Brasileira (Online)
repository_id_str
spelling Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcomaCarcinoma 256, WalkerTacrolimusTacrolimus Binding ProteinsRatsPURPOSE: To evaluate the development of Walker 256 tumor in male Wistar rats treated with tacrolimus using an experimental kidney tumor model. METHODS: 40 male Wistar rats were divided into four groups: Tumor group (TU) (n=10), Tacrolimus-Tumor group (TT) (n=10), Tacrolimus group (TC) (n=10) and Control group (C) (n=10). Treatment with tacrolimus was performed in groups TT and TC. Under anesthesia, the right kidney of each animal of TU and TT was accessed through a supraumbilical incision and inoculated with a 0.1mL solution containing 2x10(6) tumor cells (Walker 256 carcinosarcoma tumor cells). Group TC was treated with a saline solution. All the animals of groups TC and TT were treated with tacrolimus (5mg/kg/day) by gavage for 15 days. TU group animals received saline by gavage for 15 days. On the 15th postoperative day, all animals were submitted to euthanasia and blood sampling for analysis of serum creatinine (Cr) and blood urea nitrogen (BUN). Abdominal gross examination was performed, the right kidney removed and prepared for histological analysis by hematoxylin-eosin staining. The resulting data were submitted to statistical analysis by ANOVA. RESULTS: Statistical significance was found when comparing creatinine level between groups TU, TT and TC -TT group culminated with a marked increased in creatinine levels (Cr=1.013 ± 0.3028 mg/mL), TU group (Cr=0.5670 ± 0.03536 mg/dL) P=0.00256, TC group (Cr =0.711 ± 0.1653 mg/mL) P= 0.02832. Statistical significance was found when comparing BUN levels in TT group (71.32 ± 17.14 mg/mL), compared with TU group (45.83 ± 5.046 mg/dL), P=0.000318. There were no statistically significant differences between groups TT and TC (61.23 ± 9.503 mg/mL) P=0.7242. Histological analysis showed a poor evolution in TT group with multiple foci of hemorrhage and cortical invasion by the Walker tumor. CONCLUSION: The Tacrolimus-treated group developed a more aggressive tumor and a drug-related nephrotoxic effect.Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia2010-02-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502010000100020Acta Cirúrgica Brasileira v.25 n.1 2010reponame:Acta Cirúrgica Brasileira (Online)instname:Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia (SBDPC)instacron:SBDPC10.1590/S0102-86502010000100020info:eu-repo/semantics/openAccessInácio,Cristiano MachadoDietz,Ulrich AndréasMalafaia,OsvaldoRibas Filho,Jurandir MarcondesNassif,Paulo Afonso NunesCzeczko,Nicolau GregoriMarcondes,Carmen Australia Paredeseng2010-02-04T00:00:00Zoai:scielo:S0102-86502010000100020Revistahttps://www.bvs-vet.org.br/vetindex/periodicos/acta-cirurgica-brasileira/https://old.scielo.br/oai/scielo-oai.php||sgolden@terra.com.br0102-86501678-2674opendoar:2010-02-04T00:00Acta Cirúrgica Brasileira (Online) - Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia (SBDPC)false
dc.title.none.fl_str_mv Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma
title Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma
spellingShingle Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma
Inácio,Cristiano Machado
Carcinoma 256, Walker
Tacrolimus
Tacrolimus Binding Proteins
Rats
title_short Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma
title_full Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma
title_fullStr Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma
title_full_unstemmed Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma
title_sort Action of tacrolimus on Wistar rat kidneys implanted with Walker 256 carcinosarcoma
author Inácio,Cristiano Machado
author_facet Inácio,Cristiano Machado
Dietz,Ulrich Andréas
Malafaia,Osvaldo
Ribas Filho,Jurandir Marcondes
Nassif,Paulo Afonso Nunes
Czeczko,Nicolau Gregori
Marcondes,Carmen Australia Paredes
author_role author
author2 Dietz,Ulrich Andréas
Malafaia,Osvaldo
Ribas Filho,Jurandir Marcondes
Nassif,Paulo Afonso Nunes
Czeczko,Nicolau Gregori
Marcondes,Carmen Australia Paredes
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Inácio,Cristiano Machado
Dietz,Ulrich Andréas
Malafaia,Osvaldo
Ribas Filho,Jurandir Marcondes
Nassif,Paulo Afonso Nunes
Czeczko,Nicolau Gregori
Marcondes,Carmen Australia Paredes
dc.subject.por.fl_str_mv Carcinoma 256, Walker
Tacrolimus
Tacrolimus Binding Proteins
Rats
topic Carcinoma 256, Walker
Tacrolimus
Tacrolimus Binding Proteins
Rats
description PURPOSE: To evaluate the development of Walker 256 tumor in male Wistar rats treated with tacrolimus using an experimental kidney tumor model. METHODS: 40 male Wistar rats were divided into four groups: Tumor group (TU) (n=10), Tacrolimus-Tumor group (TT) (n=10), Tacrolimus group (TC) (n=10) and Control group (C) (n=10). Treatment with tacrolimus was performed in groups TT and TC. Under anesthesia, the right kidney of each animal of TU and TT was accessed through a supraumbilical incision and inoculated with a 0.1mL solution containing 2x10(6) tumor cells (Walker 256 carcinosarcoma tumor cells). Group TC was treated with a saline solution. All the animals of groups TC and TT were treated with tacrolimus (5mg/kg/day) by gavage for 15 days. TU group animals received saline by gavage for 15 days. On the 15th postoperative day, all animals were submitted to euthanasia and blood sampling for analysis of serum creatinine (Cr) and blood urea nitrogen (BUN). Abdominal gross examination was performed, the right kidney removed and prepared for histological analysis by hematoxylin-eosin staining. The resulting data were submitted to statistical analysis by ANOVA. RESULTS: Statistical significance was found when comparing creatinine level between groups TU, TT and TC -TT group culminated with a marked increased in creatinine levels (Cr=1.013 ± 0.3028 mg/mL), TU group (Cr=0.5670 ± 0.03536 mg/dL) P=0.00256, TC group (Cr =0.711 ± 0.1653 mg/mL) P= 0.02832. Statistical significance was found when comparing BUN levels in TT group (71.32 ± 17.14 mg/mL), compared with TU group (45.83 ± 5.046 mg/dL), P=0.000318. There were no statistically significant differences between groups TT and TC (61.23 ± 9.503 mg/mL) P=0.7242. Histological analysis showed a poor evolution in TT group with multiple foci of hemorrhage and cortical invasion by the Walker tumor. CONCLUSION: The Tacrolimus-treated group developed a more aggressive tumor and a drug-related nephrotoxic effect.
publishDate 2010
dc.date.none.fl_str_mv 2010-02-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502010000100020
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502010000100020
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0102-86502010000100020
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
publisher.none.fl_str_mv Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
dc.source.none.fl_str_mv Acta Cirúrgica Brasileira v.25 n.1 2010
reponame:Acta Cirúrgica Brasileira (Online)
instname:Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia (SBDPC)
instacron:SBDPC
instname_str Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia (SBDPC)
instacron_str SBDPC
institution SBDPC
reponame_str Acta Cirúrgica Brasileira (Online)
collection Acta Cirúrgica Brasileira (Online)
repository.name.fl_str_mv Acta Cirúrgica Brasileira (Online) - Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia (SBDPC)
repository.mail.fl_str_mv ||sgolden@terra.com.br
_version_ 1752126439928365056